Live tape
Top 8, mentions 7d14,365NVDA4,867 mentions▲ +0.04GOOGL2,064 mentions▲ +0.04SPY1,738 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,112 mentions▲ +0.05TSLA956 mentions▲ +0.04SNDK862 mentions▲ +0.06

Equity · Healthcare

HRTX

NASDAQ

Heron Therapeutics (HRTX)

0.474 USD −4.72% vs prior close
Heron Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
90.2M USD
Revenue, year to Dec 2025
154.9M USD
EPS, diluted, year to Dec 2025
−0.12 USD
Avg volume
402.2K

as of Jul 17, 2026

Have Heron Therapeutics (HRTX) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, no Heron Therapeutics insider bought or sold shares on the open market; all 20 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).

Form 4, 90 days to 10 Nov 2026, newest Form 4 filing 31 Oct 2026

0buys
0sells
20other filings
Have Heron Therapeutics (HRTX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
31 Oct 2026Collard Craig AChief Executive OfficerOption exercise34,788
31 Oct 2026Collard Craig AChief Executive OfficerTax withheld8,4712K USD
31 Oct 2026Duarte IraEVP, Chief Financial OfficerOption exercise11,695
31 Oct 2026Duarte IraEVP, Chief Financial OfficerTax withheld3,327932 USD
31 Oct 2026Forbes William PEVP, Chief Development OfficerOption exercise11,695
31 Oct 2026Forbes William PEVP, Chief Development OfficerTax withheld3,327932 USD
30 Oct 2026Collard Craig AChief Executive OfficerOption exercise50,021
30 Oct 2026Collard Craig AChief Executive OfficerTax withheld12,1813K USD
30 Oct 2026Duarte IraEVP, Chief Financial OfficerOption exercise13,535
30 Oct 2026Duarte IraEVP, Chief Financial OfficerTax withheld3,8501K USD
30 Oct 2026Forbes William PEVP, Chief Development OfficerOption exercise11,770
30 Oct 2026Forbes William PEVP, Chief Development OfficerTax withheld3,349938 USD

Showing the 12 most recent of 20 compensation filings in this window. The figures above count all of them.

Which funds hold Heron Therapeutics (HRTX)?

6 of the 45 institutional funds we track reported a Heron Therapeutics position for the quarter ended 30 Jun 2026 — a combined 4.2M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Heron Therapeutics (HRTX)?
FundPositionSharesValueShares q/q
Millennium ManagementTrimmed4,070,1011.7M USD−46.7%
Marshall WaceNew position2,354,1931.0M USD
AQR Capital ManagementAdded1,553,857663K USD+142.2%
Renaissance TechnologiesHeld (±25%)1,506,900643K USD−12.3%
Two Sigma InvestmentsHeld (±25%)266,314114K USD−16.1%
D. E. Shaw & Co.Trimmed120,43551K USD−95.4%
Citadel AdvisorsExited

What has been filed or recorded for Heron Therapeutics (HRTX)?

The filings we hold for Heron Therapeutics, newest first: 7 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Heron Therapeutics (HRTX)?
And
13 Oct 2026Fails to deliverShares failed to deliver33,304 shares14K USD notional · 0.018% of shares out
08 Oct 2026Fails to deliverShares failed to deliver504 shares192 USD notional · <0.001% of shares out
02 Oct 2026Fails to deliverShares failed to deliver185,466 shares67K USD notional · 0.098% of shares out
01 Oct 2026Fails to deliverShares failed to deliver331 shares103 USD notional · <0.001% of shares out
30 Sep 2026Fails to deliverShares failed to deliver210,633 shares65K USD notional · 0.111% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.03 USD
30 Sep 2026FinancialsTotal assets230.4M USDat period end
30 Sep 2026FinancialsTotal equity4.9M USDat period end
29 Sep 2026Fails to deliverShares failed to deliver72,430 shares21K USD notional · 0.038% of shares out
28 Sep 2026Fails to deliverShares failed to deliver132,709 shares38K USD notional · 0.070% of shares out
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.03 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.04 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −0.12 USD
31 Dec 2025FinancialsRevenue154.9M USDfiscal year
31 Dec 2025FinancialsNet income−20.2M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−0.12 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.10 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.02 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS 0.01 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −0.09 USD

What do people ask about Heron Therapeutics (HRTX)?

From live data
What is Heron Therapeutics’ market cap?90.2M

Heron Therapeutics is worth 90.2M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

What is Heron Therapeutics’ revenue?154.9M

Heron Therapeutics reported revenue of 154.9M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Heron Therapeutics insiders bought or sold shares recently?20 filings

In the 90 days to 10 Nov 2026, no Heron Therapeutics insider bought or sold shares on the open market; all 20 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders

Which funds own Heron Therapeutics?6 of 45

6 of the 45 funds we track reported a Heron Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Marshall Wace and AQR Capital Management. See Funds

When did Heron Therapeutics last report earnings?−0.03

Heron Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.03 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings